No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
01877 JUNSHI BIO
- 11.080
- +0.340+3.17%
Noon Break Apr 29 12:00 CST
10.92BMarket Cap-4338P/E (TTM)
11.300High10.760Low866.20KVolume10.760Open10.740Pre Close9.67MTurnover0.40%Turnover RatioLossP/E (Static)985.69MShares29.95052wk High1.38P/B2.43BFloat Cap9.17052wk Low--Dividend TTM219.30MShs Float97.150Historical High--Dividend LFY5.03%Amplitude9.170Historical Low11.167Avg Price200Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Hong Kong's Department of Health has approved a new drug application for Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) cancer drug toripalimab, according to a Wednesday release filed with the Ho
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the
Junshi Biotech (01877) appoints Wang Zhengyu as board secretary
Zhitong Finance App News, Junshi Biotech (01877) issued an announcement. Due to career development reasons, Chen Yingge applied to resign as secretary of the company's board of directors, joint company secretary and authorized representative. The resignation took effect from the date it was delivered to the company's board of directors. After Chen Yingge's resignation, he will no longer hold any position in the company. Furthermore, after the qualification review of the nomination committee of the 3rd board of directors of the company, the company held the 30th meeting of the 3rd board of directors on April 24, 2024 to review and pass the “Proposal on Appointing the Company's Board Secretary, Joint Company Secretary and Authorized Representative”. The details are as follows: Wang Zhengyu was appointed as the secretary of the company's board of directors
Junshi Biotech (01877.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Junshi Biotech (01877.HK) issued an announcement. The board of directors hereby announces that it will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's unaudited financial results for the three months ended March 31, 2024.
君實生物：董事會召開日期
Comments
The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83% 1
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.
Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.
ColumnsAnxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released
Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg